Drugs / Cardunilizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06114173 | Nov 2022 → Jun 2023 | soft tissue sarcoma | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cardunilizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06114173 ↗ |
| Known as | cardunculizumab | “The "two-in-one" dual-antibody cardunculizumab, which is more potent and less toxic, has been approved for marketing by the Fast Track Review.” NCT06114173 ↗ |